Sodium Citrate and Citric Acid Oral Solution USP

Manufacturer
AvPAK
Effective date
2025-01-09
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
full-release
Hydrated at
2026-05-31 21:22:43

Label at a glance#

ProductSodium Citrate and Citric Acid
Active ingredientSODIUM CITRATE, ANHYDROUS CITRIC ACID
Label structure16 sections

Indications and uses

Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contra...

Dosage and administration

Sodium Citrate and Citric Acid Oral Solution USP should be taken diluted in water, followed by additional water, if desired. SHAKE WELL BEFORE USING.

Storage and handling

Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from freezing.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

A Sugar-Free Systemic Alkalizer

DESCRIPTION

DESCRIPTION SECTION

Sodium Citrate and Citric Acid Oral Solution USP is a stable and pleasant-tasting systemic alkalizer containing sodium citrate and citric acid in a sugar-free base. It is a nonparticulate neutralizing buffer.

Sodium Citrate and Citric Acid Oral Solution USP contains in each teaspoonful (5 mL):

SODIUM CITRATE Dihydrate 500 mg (0.34 Molar)



CITRIC ACID Monohydrate 334 mg (0.32 Molar)

Each mL contains 1 mEq sodium ion and is equivalent to 1 mEq bicarbonate (HCO3).

INACTIVE INGREDIENTS: Flavoring, purified water, sodium benzoate, and sucralose solution.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sodium citrate is absorbed and metabolized to sodium bicarbonate, thus acting as a systemic alkalizer. The effects are essentially those of chlorides before absorption and those of bicarbonates subsequently. Oxidation is virtually complete so that less than 5% of sodium citrate is excreted in the urine unchanged.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Sodium Citrate and Citric Acid Oral Solution USP is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively.

Sodium Citrate and Citric Acid Oral Solution USP is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Patients on sodium-restricted diets or with severe renal impairment.

PRECAUTIONS

PRECAUTIONS SECTION

Sodium Citrate and Citric Acid Oral Solution USP should be used with caution by patients with low urinary output unless under the supervision of a physician. This product should not be administered concurrently with aluminum-based antacids. Patients should be directed to dilute adequately with water and preferably, to take each dose after meals to avoid saline laxative effect. Sodium salts should be used cautiously in patients with cardiac failure, hypertension, impaired renal function, peripheral and pulmonary edema, and toxemia of pregnancy. Periodic examinations and determinations of serum electrolytes, particularly serum bicarbonate level, should be carried out in those patients with renal disease in order to avoid these complications.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Sodium Citrate and Citric Acid Oral Solution USP is generally well tolerated, without any unpleasant side effects, when given in recommended doses to patients with normal renal function and urinary output. However, as with any alkalinizing agent, caution must be used in certain patients with abnormal renal mechanisms to avoid development of alkalosis, especially in the presence of hypocalcemia.

To report SUSPECTED ADVERSE REACTIONS, contact AvKARE at 1-800-361-3993 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch..

OVERDOSAGE

OVERDOSAGE SECTION

Overdosage with sodium salts may cause diarrhea, nausea and vomiting, hypernoia, and convulsions.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Sodium Citrate and Citric Acid Oral Solution USP should be taken diluted in water, followed by additional water, if desired. SHAKE WELL BEFORE USING.

For Systemic Alkalization

SPL UNCLASSIFIED SECTION

Usual Adult Dose

SPL UNCLASSIFIED SECTION

2 to 6 teaspoonfuls (10 to 30 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician.

Usual Pediatric Dose

SPL UNCLASSIFIED SECTION

1 to 3 teaspoonfuls (5 to 15 mL), diluted in 1 to 3 ounces of water, after meals and at bedtime, or as directed by a physician. For children under two years of age, use is based on consultation with a physician.

As a neutralizing buffer

SPL UNCLASSIFIED SECTION

3 teaspoonfuls (15 mL), diluted with 15 mL water, taken as a single dose, or as directed by a physician.

HOW SUPPLIED

HOW SUPPLIED SECTION

Sodium Citrate and Citric Acid Oral Solution USP (colorless, cherry flavor) is supplied in the following oral dosage forms:

NDC 50268-182-11: 15 mL unit dose cup
NDC 50268-182-15: Case contains 40 unit dose cups of 15 mL
NDC 50268-183-11: 30 mL unit dose cup
NDC 50268-183-30: Case contains 40 unit dose cups of 30 mL

STORAGE:

STORAGE AND HANDLING SECTION

Keep tightly closed. Store at controlled room temperature, 20°-25°C (68°-77°F). Protect from freezing.

SPL UNCLASSIFIED SECTION

Rx ONLY

Manufactured for:

AvKARE
Pulaski, TN 38478
Rev. 04/23

PRINCIPAL DISPLAY PANEL - 15 mL Unit Dose Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

1515

PRINCIPAL DISPLAY PANEL - 30 mL Unit Dose Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

3030

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
543014citric acid 334 MG / sodium citrate 500 MG in 5 mL Oral SolutionPSN2
543014citric acid 66.8 MG/ML / sodium citrate 100 MG/ML Oral SolutionSCD2
543014citric acid 1002 MG / sodium citrate 1500 MG per 15 ML Oral SolutionSY2
543014citric acid 2004 MG / sodium citrate 3000 MG per 30 ML Oral SolutionSY2
543014citric acid 334 MG / sodium citrate 500 MG per 5 ML Oral SolutionSY2

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
ANHYDROUS CITRIC ACID Pharmacologic Class Indexing3Indexing - Pharmacologic Class20180813

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
50268-182-11Sodium Citrate and Citric Acid15 mL in 1 CUP, UNIT-DOSESOLUTION152
50268-182-15Sodium Citrate and Citric Acid40 in 1 CARTONSOLUTION402
50268-183-11Sodium Citrate and Citric Acid30 mL in 1 CUP, UNIT-DOSESOLUTION302
50268-183-30Sodium Citrate and Citric Acid40 in 1 CARTONSOLUTION402

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
50268-182SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE AND CITRIC ACID MONOHYDRATE) SOLUTION [AVPAK]2Current NDC, 2 package rows20250112_fe070e2e-3e72-fb84-e053-6294a90afd88.zip
50268-183SODIUM CITRATE AND CITRIC ACID (SODIUM CITRATE AND CITRIC ACID MONOHYDRATE) SOLUTION [AVPAK]2Current NDC, 2 package rows20250112_fe070e2e-3e72-fb84-e053-6294a90afd88.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
50268-182-11ML - Milliliter50268-182e2f69a0a-fdc5-486a-8889-9bbf3bf382b812023-08-08
50268-182-15ML - Milliliter50268-18280a1c9f4-a596-476e-95f1-805beb0d8b0112023-08-08
50268-183-11ML - Milliliter50268-183cc0569e9-e12e-411d-b098-1413913c92f012023-08-08
50268-183-30ML - Milliliter50268-183ec5a24a3-81bf-466c-a29f-bb7ea6f3e47f12023-08-08

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
50268-18250268-182-11, 50268-182-15
50268-18350268-183-11, 50268-183-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Sodium Citrate and Citric AcidSODIUM CITRATE AND CITRIC ACID MONOHYDRATEAvPAKfe070e2e-3e72-fb84-e053-6294a90afd882025-01-09Adverse reactionsExact identifier
ndc (package): 50268-182-15
ndc (package): 50268-183-11
ndc (package): 50268-182-11
ndc (package): 50268-183-30
ndc (product): 50268-182
ndc (product): 50268-183
ndc11 (package): 50268018330
ndc11 (package): 50268018215
ndc11 (package): 50268018311
ndc11 (package): 50268018211
spl id: 2b48bae3-c39f-1035-e063-6394a90a2cc8
spl set id: fe070e2e-3e72-fb84-e053-6294a90afd88

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.